EUCTR2012-005696-14-GB进行中（未招募）1 期
A phase 3 randomised non-inferiority trial to evaluate the use of imatinib, nilotinib and ponatinib in patients with newly-diagnosed chronic phase chronic myeloid leukaemia - SPIRIT 3 - study to evaluate best use of TKIs in chronic phase CM
ewcastle upon Tyne Hospitals NHS Foundation Trust0 个研究点目标入组 1,000 人开始时间: 2013年8月14日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 1,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Male or female patients = 18 years of age. 2. Patients must fulfill all of the following: i) be diagnosed with chronic phase CML confirmed by blood morphology and RT-PCR for BCR-ABL. ii) be enrolled within 3 months of initial diagnosis of chronic phase CML (date of RT-PCR confirming presence of BCR-ABL) iii) be in confirmed chronic phase ie: a) < 15% blasts in blood (manual differential) b) < 30% blasts plus promyelocytes in blood c) < 20 % basophils in blood d) = 100 x 109 /L platelets e) no evidence of extramedullary leukaemic involvement, with the exception of hepatosplenomegaly 3.Written voluntary informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 600
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 400
排除标准
- •1. Any prior treatment for CML with any TKI (eg imatinib, dasatinib, nilotinib, bosutinib, ponatinib); busulphan, IFN-alpha, homoharringtonine, cytosine arabinoside, any other investigational agents. 2. Patients who have received prior CML chemotherapy including regimens used in peripheral blood progenitor cells (PBPCs) mobilisation for haematopoietic progenitor-cell transplantation. (collection of unmobilised PBPCs is allowed at diagnosis). 3. Patients who have had any form of prior haematopoietic stem cell transplant (autograft or allograft). 4. Patients with an ECOG Performance Status Score = 3 5. Patients with serum bilirubin, SGOT/AST, SGPT/ALT or creatinine concentrations > 2.0 x upper limit of normal (ULN) 6. Patients with serum amylase or lipase > 1.5 x ULN, history of acute pancreatitis within 1 year of study, history of chronic pancreatitis, or uncontrolled hypertriglyceridaemia (triglycerides > 450 mg/dL) 7. Patients with significant uncontrolled or active cardiovascular disease, specifically including, but not restricted to a) myocardial infarction, unstable angina and/or congestive heart failure within 6 months prior to study; and b) history of clinically significant atrial arrhythmia; or any ventricular arrhythmia. 8. Patients taking medications known to be associated with Torsade de Pointes (eg amiodarone, azithromycin, chloroquine, citalopram, domperidone, erythromycin, quinidine, sotalol, thioridazine) 9. Patients with known uncontrolled hypertension; systolic blood pressure > 140mm Hg and/or diastolic blood pressure > 90mm Hg 10. Patients with a known INR or PTT > 1.5 x ULN, with the exception of patients on treatment with oral anticoagulants, or patients with a known bleeding disorder. Baseline testing of INR is not required. 11. Patients with uncontrolled medical disease such as diabetes mellitus, thyroid dysfunction, neuropsychiatric disorders or infection. 12. Patients who have undergone major surgery within 4 weeks of starting trial IMP. 13. Patients who are: a) pregnant b) breast feeding c) of childbearing potential without a negative pregnancy test prior to starting trial IMP and d) male or female of childbearing potential unwilling to use barrier contraceptive precautions throughout the trial (postmenopausal women must be amenorrhoeic for at least 12 months to be considered of non-childbearing potential). 14. Patients with a history of another malignancy either currently or within the past five years (with the exception of basal cell skin carcinoma in situ). 15. Patients with a history of non-compliance to medical regimens or patients who can envisage being unable to complete the study for any reason. 16. Patients unwilling to receive trial drug via a home delivery method.
研究者
相似试验
已完成
3 期
SPIRIT 3: To evaluate the most effective way to use imatinib, nilotinib and ponatinib in the treatment of chronic myeloid leukaemiaChronic myeloid leukaemiaChronic myeloid leukaemia [CML], BCR/ABL-positiveCancerISRCTN60655195ewcastle-upon-Tyne Hospitals NHS Foundation Trust (UK)1,000
已完成
不适用
A phase III, randomised, non-inferiority trial, to assess the efficacy and safety of dihydroartemisinin and piperaquine (DHA + PPQ, Artekin®) in comparison with artesunate and mefloquine (AS + MQ) in patients affected by acute, uncomplicated Plasmodium falciparum malariaMalariaISRCTN81306618Sigma-Tau (Italy)1,050
已完成
不适用
A phase III, randomised, non-inferiority trial, to assess the efficacy and safety of Dihydroartemisinin and Piperaquine (DHA + PPQ, Artekin®) in comparison with Artemether and Lumefantrine (A + L, Coartem®) in children with uncomplicated Plasmodium falciparum malariaInfections and InfestationsPlasmodium falciparum malariaMalariaISRCTN16263443Sigma-Tau (Italy)1,500
招募中
1 期
Trial in patients with newly diagnosed myeloma to assess non-inferiority of induction therapy with isatuximab/lenalidomide/ bortezomib/ dexamethasone when isatuximab is administered subcutaneously versus intravenouslyewly diagnosed symptomatic multiple myelomaMedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2022-000996-38-ATRuprecht-Karls-Universität Heidelberg, Medical Faculty represented by Universitätsklinikum Heidelberg514
招募中
1 期
Trial in patients with newly diagnosed myeloma to assess non-inferiority of induction therapy with isatuximab/lenalidomide/ bortezomib/ dexamethasone when isatuximab is administered subcutaneously versus intravenouslyewly diagnosed symptomatic multiple myelomaMedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2022-000996-38-DERuprecht-Karls-Universität Heidelberg, Medical Faculty represented by Universitätsklinikum Heidelberg514